Anti-corruption compliance lessons from Teva’s FCPA case
Teva Pharmaceuticals conducted bribery on a massive, international scale and became a case study for FCPA watchers everywhere. Jaclyn Jaeger reports.
Related articles
-
ArticleTeva to pay $54M in FCA whistleblower settlement
Teva Pharmaceuticals has reached a $54 million settlement in a lawsuit filed by two whistleblowers over allegations the drug company bribed physicians through numerous “sham” speaker programs in exchange for prescribing Teva drugs.
-
News BriefChipmaker fined $140M for unlawfully exporting chip design tools to China
Chip design software and hardware maker Cadence Design Systems agreed to plead guilty to unlawfully exporting semiconductor design tools to a restricted Chinese military university, the Department of Justice said in a statement. The California firm will pay over $140 million in criminal and civil pines and forfeitures, marking the ...
-
News BriefSEC reportedly denying record percentage of whistleblower claims
The Securities and Exchange Commission is awarding far fewer whistleblower claims, according to Bloomberg Law, which noted the commission denied awards for the entire period between April and July, the longest stretch in the program’s history.